Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes
Abstract Patients with cancer demonstrate particularly poor outcomes from COVID-19. To provide information essential for understanding the biologic underpinnings of this association, we analyzed whole-transcriptome RNA expression data obtained from a large cohort of cancer patients to characterize e...
Guardado en:
Autores principales: | Andrew Elliott, Michelle Saul, Jia Zeng, John L. Marshall, Edward S. Kim, Misako Nagasaka, Heinz-Josef Lenz, Lee Schwartzberg, David Spetzler, Jim Abraham, Joanne Xiu, Phillip Stafford, W. Michael Korn |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/de659d81a8a243fe8527f66b921f70ed |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
por: Zhang C, et al.
Publicado: (2021) -
Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019
por: Marco Rossato, et al.
Publicado: (2020) -
Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: Anti-arrhythmic Drug for Arrhythmogenic Right Ventricular Cardiomyopathy
por: Bin Tu, et al.
Publicado: (2021) -
New perspectives in the renin-angiotensin-aldosterone system (RAAS) I: endogenous angiotensin converting enzyme (ACE) inhibition.
por: Miklós Fagyas, et al.
Publicado: (2014) -
Angiotensin-converting enzyme polymorphisms AND Alzheimer's disease susceptibility: An updated meta-analysis.
por: Xiao-Yu Xin, et al.
Publicado: (2021)